Exact peptide identities attached to retained registry observations carrying this condition label.
Coverage-gated living condition brief
Healthy peptide evidence brief
A cited Healthy peptide evidence brief across 25 exact-label ClinicalTrials.gov records, 14 connected profiles, and 8 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
25 selected records.
14 profiles.
2012–2026 in selected records.
Direct collection answer · published August 17, 2026
What peptide evidence does PeptideScanner carry for Healthy?
PeptideScanner’s selected collection contains 25 retained ClinicalTrials.gov records carrying the exact condition label “Healthy,” connected to 14 peptide profiles across 8 registry-update years.
That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Healthy, and it is not a safety or efficacy assessment.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 320 selected PubMed records and 37 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Healthy unless their own cited source says so.
Related profile context
Literature connected through these peptide profiles
This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Healthy.
Orforglipron · source record 2026-11-09
Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.
PubMed lists PMID 41994902 in Diabetes, obesity & metabolism as Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Survodutide · source record 2026-10-19
Interpreting Survodutide Renoprotection in a Hyperfiltration Model.
PubMed lists PMID 42897119 in Diabetes, obesity & metabolism as Letter, with publication-date metadata of 2026-10-19 (day precision). PeptideScanner associated the retained record with the identity slug survodutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Efinopegdutide · source record 2026-11-09
Efinopegdutide: a step towards precision in MASH therapy?
PubMed lists PMID 43003104 in Lancet (London, England) as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug efinopegdutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Semaglutide · source record 2026-11-12
Semaglutide and alcohol use disorder: An evidence gap India must fill.
PubMed lists PMID 43011941 in Indian journal of psychiatry as Letter, with publication-date metadata of 2026-10-21 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Liraglutide · source record 2026-10-18
Epicardial Versus Circulating Adiponectin: An Unresolved Distinction in Liraglutide's Anti-Arrhythmic Mechanism.
PubMed lists PMID 42891862 in Cardiovascular drugs and therapy as Letter, with publication-date metadata of 2026-10-17 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Afamelanotide · source record 2026-01-18
From darkness to light: Case report on afamelanotide-treatment in a 9-year-old child with erythropoietic protoporphyria.
PubMed lists PMID 41542313 in JAAD case reports as Case Reports, Journal Article, with publication-date metadata of 2025-11-24 (day precision). PeptideScanner associated the retained record with the identity slug afamelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT00386490
PeptideScanner retained ClinicalTrials.gov record NCT00386490 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- September 12, 2017
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT01093729
PeptideScanner retained ClinicalTrials.gov record NCT01093729 at 2026-11-16T17:34:46.889Z. Its registry update date was 2014-02-07, and PeptideScanner's reviewed identity mapping was efpeglenatide.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- February 7, 2014
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT03606057
PeptideScanner retained ClinicalTrials.gov record NCT03606057 at 2026-11-16T17:46:45.897Z. Its registry update date was 2020-03-03, and PeptideScanner's reviewed identity mapping was efinopegdutide.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- March 3, 2020
- Evidence lane
- Clinical trials
Exact-record source chronology
Healthy registry timeline
Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.
2026
10 recordsSurvodutide · 2026-11-16
ClinicalTrials.gov record NCT07940244
Not yet recruiting at the retained observation.
Open cited registry record →Eloralintide · 2026-11-13
ClinicalTrials.gov record NCT07935304
Not yet recruiting at the retained observation.
Open cited registry record →Liraglutide · 2026-10-28
ClinicalTrials.gov record NCT04466566
Completed at the retained observation.
Open cited registry record →Survodutide · 2026-10-28
ClinicalTrials.gov record NCT07768813
Active, not recruiting at the retained observation.
Open cited registry record →Survodutide · 2026-10-27
ClinicalTrials.gov record NCT07221591
Completed at the retained observation.
Open cited registry record →Orforglipron · 2026-07-17
ClinicalTrials.gov record NCT06370728
Completed at the retained observation.
Open cited registry record →Orforglipron · 2026-07-17
ClinicalTrials.gov record NCT06440980
Completed at the retained observation.
Open cited registry record →Survodutide · 2026-06-15
ClinicalTrials.gov record NCT07413913
Completed at the retained observation.
Open cited registry record →Orforglipron · 2026-05-26
ClinicalTrials.gov record NCT06704763
Completed at the retained observation.
Open cited registry record →Orforglipron · 2026-05-22
ClinicalTrials.gov record NCT06186622
Completed at the retained observation.
Open cited registry record →2025
3 recordsEfinopegdutide · 2025-02-26
ClinicalTrials.gov record NCT06701305
Completed at the retained observation.
Open cited registry record →Efinopegdutide · 2025-02-21
ClinicalTrials.gov record NCT06836037
Completed at the retained observation.
Open cited registry record →Pasireotide · 2025-02-19
ClinicalTrials.gov record NCT03847207
Completed at the retained observation.
Open cited registry record →2021
1 recordGlepaglutide · 2021-07-14
ClinicalTrials.gov record NCT04318743
Completed at the retained observation.
Open cited registry record →2020
2 recordsSecretin · 2020-06-11
ClinicalTrials.gov record NCT03617861
Completed at the retained observation.
Open cited registry record →Efinopegdutide · 2020-03-03
ClinicalTrials.gov record NCT03606057
Completed at the retained observation.
Open cited registry record →2018
3 recordsAfamelanotide · 2018-08-16
ClinicalTrials.gov record NCT03634137
Completed at the retained observation.
Open cited registry record →Semaglutide · 2018-06-13
ClinicalTrials.gov record NCT02064348
Completed at the retained observation.
Open cited registry record →Semaglutide · 2018-04-18
ClinicalTrials.gov record NCT02146079
Completed at the retained observation.
Open cited registry record →2017
3 recordsLarazotide · 2017-09-12
ClinicalTrials.gov record NCT00386490
Completed at the retained observation.
Open cited registry record →Vasopressin · 2017-06-05
ClinicalTrials.gov record NCT02223429
Completed at the retained observation.
Open cited registry record →Semaglutide · 2017-04-04
ClinicalTrials.gov record NCT02022254
Completed at the retained observation.
Open cited registry record →2014
2 recordsLiraglutide · 2014-02-27
ClinicalTrials.gov record NCT01550653
Completed at the retained observation.
Open cited registry record →Efpeglenatide · 2014-02-07
ClinicalTrials.gov record NCT01093729
Completed at the retained observation.
Open cited registry record →2012
1 recordTeduglutide · 2012-05-07
ClinicalTrials.gov record NCT01028924
Completed at the retained observation.
Open cited registry record →- Condition matching is limited to exact labels on retained ClinicalTrials.gov v3 observations; PeptideScanner does not merge related diagnoses or synonyms.
- Coverage is selective and historical, not a complete or continuously current account of the registry or PubMed.
- The brief does not synthesize study outcomes, compare interventions, or make safety, efficacy, diagnosis, or treatment claims.